cas 347-54-6|| where to buy 5-Fluoro-2-hydroxybenzaldehyde

Product Name:5-Fluoro-2-hydroxybenzaldehyde

IUPAC Name:5-fluoro-2-hydroxybenzaldehyde

Packing Unit	Available Stock	Price($)
CM252379-25g	in stock	ƞĽ
CM252379-100g	in stock	ȎƄǯ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 347-54-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:347-54-6; Molecular Formula:C7H5FO2; Melting Point:-; Smiles Code:C1=C(C(=CC=C1F)O)C=O; Density:

: Catalog Number:CM252379; Molecular Weight:140.11; Boiling Point:207.4°C at 760 mmHg; MDL No:MFCD01090997; Storage:Keep in Inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Repotrectinib; Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.